Na Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Na Li has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Chenggong Yu
Department of Gastroenterology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
2 shared publications - Binlin Da
Research Institute of General Surgery, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
1 shared publication - Chengkai Zhu
Department of Gastroenterology, The Yangzhou School of Clinical Medicine of Nanjing Medical University, Yangzhou, China
1 shared publication - Minya Liu
Department of Gastroenterology, Taikang Xianlin Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
1 shared publication - Pingnan Zhang
Department of Gastroenterology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
1 shared publication - Saifei Xu
Department of Gastroenterology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
1 shared publication
Latest Publications
- Open Access
- 31 July 2026
- Published by Springer Nature in Inflammation Research
- Vol. 75 (1) , 185
Regulation of Tph cell differentiation via farnesoid X receptor of dendritic cells in inflammatory bowel disease
- 31 July 2026
- Published by Springer Nature in Inflammation Research
- Vol. 75 (1) , 185
Open AccessRegulation of Tph cell differentiation via farnesoid X receptor of dendritic cells in inflammatory bowel disease
- 5 July 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 70 (10) , 3323-3339
Faecalibacterium prausnitzii Ameliorates DSS-Induced Colitis via Modulating Bile Acid Metabolism and Regulating FXR Signaling
Background Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease with a globally increasing incidence. Faecalibacterium prausnitzii (F. prausnitzii) is known for its anti-inflammatory and immunomodulatory properties. However, the mechanisms by which gut microbiota and bile acid metabolism contribute to the therapeutic effects of F. prausnitzii in colitis remain unclear. Aims This study aims to investigate the effects of F. prausnitzii on colitis and elucidate its potential mechanism through modulation of gut microbiota and bile acid metabolism. Methods Mice were treated with dextran sulfate sodium (DSS), followed by administration of F. prausnitzii and its supernatant. Colitis symptoms, inflammatory responses, and intestinal barrier integrity were then evaluated. 16S rRNA sequencing and targeted bile acid metabolomics analysis were performed. Results F. prausnitzii and its supernatant reshaped dysbiotic gut microbiota in DSS-induced colitis mouse models, increasing the ratio of unconjugated to conjugated bile acids and secondary to primary bile acids, thereby activating the farnesoid X receptor (FXR) signaling pathway. Experiments in FXR−/− mice confirmed that FXR is a critical target for the protective effects of F. prausnitzii, promoting intestinal mucosal repair and inhibiting NLRP3 inflammasome activation, which in turn alleviates colitis. Additionally, the differential bile acid isoLCA, enriched by F. prausnitzii and its supernatant, effectively suppressed inflammation and enhanced intestinal barrier function. Conclusion This study demonstrates that F. prausnitzii alleviates colitis by modulating bile acid composition and regulating FXR signaling, suggesting that targeting the microbiota–bile acid–FXR pathway may represent a promising therapeutic strategy for inflammatory bowel disease.
- 5 July 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 70 (10) , 3323-3339
Faecalibacterium prausnitzii Ameliorates DSS-Induced Colitis via Modulating Bile Acid Metabolism and Regulating FXR Signaling
Background Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease with a globally increasing incidence. Faecalibacterium prausnitzii (F. prausnitzii) is known for its anti-inflammatory and immunomodulatory properties. However, the mechanisms by which gut microbiota and bile acid metabolism contribute to the therapeutic effects of F. prausnitzii in colitis remain unclear. Aims This study aims to investigate the effects of F. prausnitzii on colitis and elucidate its potential mechanism through modulation of gut microbiota and bile acid metabolism. Methods Mice were treated with dextran sulfate sodium (DSS), followed by administration of F. prausnitzii and its supernatant. Colitis symptoms, inflammatory responses, and intestinal barrier integrity were then evaluated. 16S rRNA sequencing and targeted bile acid metabolomics analysis were performed. Results F. prausnitzii and its supernatant reshaped dysbiotic gut microbiota in DSS-induced colitis mouse models, increasing the ratio of unconjugated to conjugated bile acids and secondary to primary bile acids, thereby activating the farnesoid X receptor (FXR) signaling pathway. Experiments in FXR−/− mice confirmed that FXR is a critical target for the protective effects of F. prausnitzii, promoting intestinal mucosal repair and inhibiting NLRP3 inflammasome activation, which in turn alleviates colitis. Additionally, the differential bile acid isoLCA, enriched by F. prausnitzii and its supernatant, effectively suppressed inflammation and enhanced intestinal barrier function. Conclusion This study demonstrates that F. prausnitzii alleviates colitis by modulating bile acid composition and regulating FXR signaling, suggesting that targeting the microbiota–bile acid–FXR pathway may represent a promising therapeutic strategy for inflammatory bowel disease.